TRU CUT Biopsy at Dr. Essa Lab

Introduction to TRU CUT Biopsy at Dr. Essa Lab

A TRU CUT biopsy, also known as a core needle biopsy, is a highly specialized interventional diagnostic procedure designed to extract a solid, cylindrical core of tissue from a suspicious mass, nodule, or organ. Unlike Fine Needle Aspiration (FNA), which only retrieves individual cells or fluid, a TRU CUT biopsy preserves the histological architecture of the tissue specimen. This structural preservation is critical for pathologists to evaluate the spatial arrangement of cells, determine tissue invasiveness, and accurately grade neoplasms. At Dr. Essa Lab, this procedure is performed under strict sterile conditions, often guided by advanced imaging modalities such as high-resolution ultrasound or computed tomography (CT) to ensure precise localization and maximum diagnostic yield.

The clinical importance of a TRU CUT biopsy lies in its ability to provide a definitive tissue diagnosis without the need for invasive surgical intervention. The obtained tissue specimen undergoes a meticulous processing sequence in our state-of-the-art histopathology laboratory, including formalin fixation, paraffin embedding, microtome sectioning, and hematoxylin and eosin (H&E) staining. When necessary, advanced immunohistochemical (IHC) markers are applied to further characterize the tumor subtype. This procedure is fundamental in oncology, urology, gynecology, and general surgery, enabling clinicians to differentiate between benign and malignant lesions, identify specific tumor lineages, and formulate highly personalized, evidence-based treatment plans. By delivering rapid and highly accurate diagnostic insights, Dr. Essa Lab plays a pivotal role in accelerating the patient care pathway and optimizing therapeutic outcomes.

Clinical Procedure: What to Expect

Patient Preparation

Proper patient preparation is essential to ensure safety, minimize complications, and guarantee the quality of the biopsy specimen. Patients undergoing a TRU CUT biopsy at Dr. Essa Lab must adhere to the following clinical guidelines:

• Coagulation Profile: Patients must undergo a baseline coagulation screen, including Prothrombin Time (PT), Activated Partial Thromboplastin Time (aPTT), and International Normalized Ratio (INR), to assess bleeding risk prior to the procedure.
• Medication Adjustment: Under the guidance of the referring physician, antiplatelet medications (such as aspirin or clopidogrel) and anticoagulants (such as warfarin or low-molecular-weight heparin) must be discontinued 5 to 7 days before the biopsy to prevent hematoma formation.
• Fasting Requirements: While a local anesthetic is typically used, patients may be advised to fast for 4 to 6 hours prior to the procedure, particularly if conscious sedation is planned or if the biopsy involves deep abdominal organs.
• Medical History Disclosure: Patients must inform the clinical team of any known allergies, particularly to local anesthetics (like lidocaine), latex, or contrast agents, as well as any history of bleeding disorders or cardiac valvular disease.
• Comfortable Attire: Patients should wear loose, comfortable clothing. Depending on the biopsy site, they may be asked to change into a sterile hospital gown.
• Accompanying Adult: It is highly recommended that patients arrange for a family member or guardian to accompany them home after the procedure, especially if sedation is administered.

During the Procedure

The TRU CUT biopsy is performed in a dedicated, sterile interventional suite at Dr. Essa Lab. The procedure typically proceeds as follows:

• Patient Positioning: The patient is positioned comfortably on an examination table. The positioning depends entirely on the target lesion; for example, a breast biopsy may require a supine or lateral decubitus position, while a prostate biopsy requires a lithotomy or left lateral decubitus position.
• Aseptic Preparation: The skin overlying the target area is meticulously cleansed with an antiseptic solution (such as chlorhexidine or povidone-iodine) and draped with sterile towels to maintain a sterile field.
• Local Anesthesia: A local anesthetic (typically 1% or 2% lidocaine) is infiltrated into the skin and subcutaneous tissues along the planned needle tract to ensure the patient experiences minimal discomfort.
• Imaging Guidance: Real-time ultrasound or CT imaging is utilized by the radiologist to visualize the lesion, plan the safest trajectory, and monitor the advancement of the biopsy needle.
• Needle Insertion and Sample Acquisition: A small skin nick (1-2 mm) is made to facilitate the entry of the TRU CUT needle. The needle, which features a outer cannula and an inner specimen notch, is advanced to the edge of the lesion. The spring-loaded mechanism is then activated, rapidly advancing the cannula over the notch to cut and capture a core of tissue. This process may be repeated 2 to 5 times through the same coaxial sheath to obtain adequate tissue samples.
• Post-Procedure Care: After the needle is withdrawn, firm manual pressure is applied to the site for 10 to 15 minutes to achieve hemostasis. A sterile compressive dressing is then applied. The patient is monitored in a recovery area for 1 to 2 hours to ensure there are no immediate complications, such as active bleeding or severe pain, before being safely discharged.

When is a TRU CUT Biopsy Performed?

Evaluation of Suspicious Breast Masses

A TRU CUT biopsy is clinically indicated when a patient presents with a palpable breast lump or when screening imaging (mammography or ultrasound) reveals a highly suspicious lesion classified as BI-RADS 4 or 5. The procedure allows for the differentiation between benign conditions, such as fibroadenomas or fibrocystic changes, and malignant breast cancers, including invasive ductal or lobular carcinoma. It also provides the tissue necessary for estrogen receptor (ER), progesterone receptor (PR), and HER2/neu receptor status testing.

Investigation of Persistent Lymphadenopathy

Physicians frequently request a TRU CUT biopsy when a patient exhibits persistent, unexplained enlargement of the lymph nodes (cervical, axillary, or inguinal) accompanied by systemic symptoms like unexplained weight loss, night sweats, or fever. The biopsy helps rule out primary hematological malignancies such as Hodgkin or Non-Hodgkin lymphoma, as well as metastatic disease originating from primary tumors in other organs, providing critical staging information.

Assessment of Suspected Prostate Malignancy

In patients presenting with elevated serum Prostate-Specific Antigen (PSA) levels or abnormal findings on a Digital Rectal Examination (DRE), a transrectal or transperineal TRU CUT biopsy is performed. Guided by transrectal ultrasound (TRUS), this procedure allows for the systematic sampling of prostate tissue to detect prostatic adenocarcinoma, determine the Gleason score, and assess the aggressiveness of the tumor to guide active surveillance, surgery, or radiation therapy.

Characterization of Deep Soft Tissue Masses

Unexplained, enlarging masses within the skeletal muscle, subcutaneous tissue, or retroperitoneum require a TRU CUT biopsy to establish a histopathological diagnosis. These lesions can range from benign lipomas and fibromas to highly aggressive soft tissue sarcomas. The core tissue sample is vital for identifying the specific histological subtype of sarcoma, which dictates the surgical margins and neoadjuvant oncological strategies.

Diagnostic Evaluation of Focal Liver and Kidney Lesions

When non-invasive imaging (ultrasound, CT, or MRI) reveals atypical or indeterminate focal lesions in the liver or kidneys, a percutaneous image-guided TRU CUT biopsy is indicated. This assists in diagnosing primary malignancies like hepatocellular carcinoma (HCC) or renal cell carcinoma (RCC), differentiating them from benign lesions (such as hemangiomas or adenomas), and identifying metastatic disease, thereby preventing unnecessary surgical resections.

What Does a TRU CUT Biopsy Detect?

A TRU CUT biopsy is highly sensitive and specific, capable of detecting a wide array of benign, pre-malignant, and malignant conditions across various organ systems. The primary findings detectable through this procedure include:

• Invasive Ductal Carcinoma (IDC) of the breast
• Invasive Lobular Carcinoma (ILC) of the breast
• Ductal Carcinoma In Situ (DCIS)
• Fibroadenoma and Phyllodes tumors
• Prostatic Adenocarcinoma (with Gleason grading)
• Benign Prostatic Hyperplasia (BPH)
• Hepatocellular Carcinoma (HCC)
• Hepatic Steatosis and Cirrhotic tissue changes
• Renal Cell Carcinoma (RCC) (e.g., clear cell, papillary)
• Renal Oncocytoma
• Hodgkin Lymphoma subtypes
• Non-Hodgkin Lymphoma (e.g., Diffuse Large B-Cell Lymphoma)
• Metastatic carcinoma in lymph nodes
• Granulomatous Lymphadenitis (including Tuberculosis)
• Reactive Lymph Node Hyperplasia
• Soft tissue sarcomas (e.g., Liposarcoma, Leiomyosarcoma)
• Benign soft tissue tumors (e.g., Lipoma, Schwannoma)
• Atypical Ductal Hyperplasia (ADH)
• Lobular Carcinoma In Situ (LCIS)
• Chronic active hepatitis and liver fibrosis
• Acute or chronic interstitial nephritis
• Autoimmune thyroiditis or thyroid nodules
• Granulomatous mastitis
• Fat necrosis of the breast
• Fibrocystic breast changes

Turnaround Time and Report Access at Dr. Essa Lab

At Dr. Essa Lab, we understand that waiting for biopsy results can be an anxious time for patients and their families. Our histopathology department is staffed by highly experienced consultant pathologists who process and review each specimen with the utmost precision. The standard turnaround time for a TRU CUT biopsy report is typically 3 to 5 working days. This timeframe ensures that the tissue undergoes proper fixation, processing, sectioning, staining, and, if required, immunohistochemical analysis to guarantee diagnostic accuracy.

Once the report is finalized and signed off by our consultant pathologist, patients are notified via SMS. Reports can be accessed instantly online through the official Dr. Essa Lab web portal or mobile application, allowing patients and their referring physicians to view and download the results from the comfort of their homes. Physical copies of the reports can also be collected from any of our conveniently located diagnostic centers across Karachi and other major cities.

TRU CUT Biopsy Findings Overview

Structure / Parameter Evaluated	Normal Findings	Possible Abnormal Findings
Breast Tissue	Normal lobules, ducts, and specialized stroma without atypia or malignancy.	Invasive Ductal Carcinoma, Fibroadenoma, Ductal Carcinoma In Situ (DCIS), Fat Necrosis.
Lymph Nodes	Preserved nodal architecture with normal lymphoid follicles and sinus histiocytes.	Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Metastatic Carcinoma, Tubercular Lymphadenitis.
Prostate Gland	Benign fibromuscular stroma and glandular elements lined by double cell layers.	Prostatic Adenocarcinoma (Gleason Score 6-10), High-Grade Prostatic Intraepithelial Neoplasia (H-PIN).
Liver Parenchyma	Normal lobular architecture, hepatocytes without steatosis, inflammation, or fibrosis.	Hepatocellular Carcinoma, Metastatic Adenocarcinoma, Cirrhosis, Steatohepatitis.
Kidney Parenchyma	Normal glomeruli, tubules, interstitium, and blood vessels.	Renal Cell Carcinoma (RCC), Oncocytoma, Glomerulonephritis, Interstitial Nephritis.
Soft Tissue Mass	Mature adipose tissue, skeletal muscle, or fibrous connective tissue without atypia.	Liposarcoma, Leiomyosarcoma, Fibromatosis, Schwannoma, Myxoid Liposarcoma.
Thyroid Gland	Normal thyroid follicles filled with colloid, lined by uniform follicular cells.	Papillary Thyroid Carcinoma, Follicular Neoplasm, Medullary Carcinoma, Hashimoto’s Thyroiditis.

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient’s symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Dr. Essa Lab for TRU CUT Biopsy?

• Legacy of Trust: Established in 1987, Dr. Essa Lab is one of Pakistan’s most trusted and recognized diagnostic networks, built on a foundation of clinical excellence.
• Highly Qualified Pathologists: Our histopathology department is led by renowned, board-certified Consultant Pathologists specializing in oncopathology and cytopathology.
• Advanced Imaging Guidance: We utilize state-of-the-art ultrasound and CT imaging systems to ensure maximum precision and safety during interventional procedures.
• ISO Certified Standards: Dr. Essa Lab adheres to strict international quality control protocols, holding prestigious ISO certifications for diagnostic accuracy.
• Patient-Focused Care: Our compassionate clinical staff ensures a comfortable, sterile, and stress-free environment for patients undergoing interventional procedures.
• Rapid Turnaround Time: We prioritize biopsy processing to deliver accurate histopathological reports within 3 to 5 working days, facilitating prompt treatment.
• Convenient Digital Access: Patients can easily download their diagnostic reports online via our secure web portal or dedicated mobile application.
• Widespread Network: With numerous branches across Karachi and other cities, accessing premium diagnostic and interventional services is highly convenient.